Selling, General, and Administrative Costs: Exelixis, Inc. vs Geron Corporation

A Decade of SG&A Trends: Exelixis, Inc. vs. Geron Corporation

In the ever-evolving landscape of biotechnology, understanding the financial health of companies is crucial. Over the past decade, Exelixis, Inc. and Geron Corporation have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Exelixis, Inc. has seen a staggering increase of over 900% in SG&A costs, reflecting its aggressive expansion and investment in operational capabilities. In contrast, Geron Corporation's SG&A expenses have grown by approximately 310%, indicating a more conservative approach.

This divergence highlights the strategic differences between the two companies. Exelixis's rapid growth in expenses suggests a focus on scaling and market penetration, while Geron's steadier increase may point to a more cautious, sustainable growth strategy. As the biotech sector continues to innovate, these financial insights provide a window into the strategic priorities of these industry players.